Similar articles

• Comment on: Insurance coverage decisions for pediatric proton therapy.

  Schefft M. Schefft M. Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26787. Epub 2017 Sep 12. Pediatr Blood Cancer. 2018. PMID: 28895289 No abstract available.
• Insurance coverage decisions for pediatric proton therapy.

  Ojerholm E, Hill-Kayser CE. Ojerholm E, et al. Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26729. Epub 2017 Aug 7. Pediatr Blood Cancer. 2018. PMID: 28782877 Clinical Trial.
• Insurance coverage, physician recommendations, and access to emerging treatments: growth hormone therapy for childhood short stature.

  Finkelstein BS, Silvers JB, Marrero U, Neuhauser D, Cuttler L. Finkelstein BS, et al. JAMA. 1998 Mar 4;279(9):663-8. doi: 10.1001/jama.279.9.663. JAMA. 1998. PMID: 9496983
• The bare necessities? A realist review of necessity argumentations used in health care coverage decisions.

  Kleinhout-Vliek T, de Bont A, Boer B. Kleinhout-Vliek T, et al. Health Policy. 2017 Jul;121(7):731-744. doi: 10.1016/j.healthpol.2017.04.011. Epub 2017 May 5. Health Policy. 2017. PMID: 28550936 Review.
• Impediments to Comparative Clinical Trials With Proton Therapy.

  Cox JD. Cox JD. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):4-8. doi: 10.1016/j.ijrobp.2015.09.036. Epub 2015 Oct 3. Int J Radiat Oncol Biol Phys. 2016. PMID: 26684408 Review. No abstract available.